Trial Profile
A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 28 Sep 2023 Status changed from active, no longer recruiting to completed.
- 01 Dec 2022 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.
- 01 Dec 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.